Enovis Co. (NYSE:ENOV) Receives $69.13 Consensus Price Target from Analysts

Shares of Enovis Co. (NYSE:ENOVGet Free Report) have been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $67.89.

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Evercore ISI dropped their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC dropped their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Finally, JMP Securities began coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price on the stock.

View Our Latest Stock Report on Enovis

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently bought and sold shares of ENOV. Handelsbanken Fonder AB boosted its stake in shares of Enovis by 32.8% in the 3rd quarter. Handelsbanken Fonder AB now owns 10,517 shares of the company’s stock valued at $453,000 after purchasing an additional 2,600 shares in the last quarter. Park Avenue Securities LLC boosted its stake in shares of Enovis by 16.3% in the 3rd quarter. Park Avenue Securities LLC now owns 10,655 shares of the company’s stock valued at $459,000 after purchasing an additional 1,493 shares in the last quarter. Truist Financial Corp boosted its stake in shares of Enovis by 73.7% in the 2nd quarter. Truist Financial Corp now owns 23,904 shares of the company’s stock valued at $1,080,000 after purchasing an additional 10,141 shares in the last quarter. Ironwood Investment Management LLC boosted its stake in shares of Enovis by 100.0% in the 2nd quarter. Ironwood Investment Management LLC now owns 13,557 shares of the company’s stock valued at $613,000 after purchasing an additional 6,779 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Enovis in the 2nd quarter valued at $250,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Down 2.6 %

NYSE:ENOV opened at $39.62 on Tuesday. Enovis has a 12 month low of $39.53 and a 12 month high of $65.03. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -26.41 and a beta of 1.91. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $43.72 and its 200-day moving average is $48.43.

Enovis (NYSE:ENOVGet Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The company had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. During the same quarter last year, the firm posted $0.61 earnings per share. The company’s quarterly revenue was up 22.6% compared to the same quarter last year. Equities analysts anticipate that Enovis will post 2.7 EPS for the current year.

About Enovis

(Get Free Report

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Recommended Stories

Analyst Recommendations for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.